Mutual of America Capital Management LLC Sells 110 Shares of Quest Diagnostics Incorporated $DGX

Mutual of America Capital Management LLC lowered its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 0.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,827 shares of the medical research company’s stock after selling 110 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Quest Diagnostics were worth $2,304,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Pinnacle Bancorp Inc. boosted its stake in shares of Quest Diagnostics by 126.9% in the 2nd quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 85 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Quest Diagnostics by 76.6% in the 1st quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 82 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Quest Diagnostics by 157.3% in the 1st quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 118 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in shares of Quest Diagnostics in the 2nd quarter valued at about $35,000. Finally, Larson Financial Group LLC boosted its stake in shares of Quest Diagnostics by 101.9% in the 1st quarter. Larson Financial Group LLC now owns 323 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 163 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Stock Performance

Shares of DGX opened at $182.51 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.99 and a current ratio of 1.13. Quest Diagnostics Incorporated has a twelve month low of $148.70 and a twelve month high of $197.55. The firm’s 50 day moving average price is $182.99 and its two-hundred day moving average price is $176.89. The firm has a market cap of $20.30 billion, a P/E ratio of 21.42, a PEG ratio of 2.40 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The firm had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter in the previous year, the firm posted $2.30 earnings per share. The business’s revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Stockholders of record on Friday, October 3rd were issued a $0.80 dividend. The ex-dividend date was Friday, October 3rd. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 2,210 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, July 31st. The shares were sold at an average price of $170.00, for a total value of $375,700.00. Following the sale, the senior vice president directly owned 8,450 shares in the company, valued at $1,436,500. This trade represents a 20.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael E. Prevoznik sold 227 shares of Quest Diagnostics stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president owned 38,117 shares in the company, valued at $7,170,951.21. This trade represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,668 shares of company stock valued at $9,917,788 over the last ninety days. 8.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Jefferies Financial Group raised their target price on shares of Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho raised their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. Baird R W lowered shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Robert W. Baird reissued a “neutral” rating and set a $194.00 price objective on shares of Quest Diagnostics in a research note on Monday, August 25th. Finally, Morgan Stanley set a $207.00 price objective on shares of Quest Diagnostics and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.31.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.